Previous 10 | Next 10 |
Gainers: Ovid Therapeutics (OVID) +48%, KemPharm (KMPH) +46%, Ocugen (OCGN) +34%, Asensus Surgical (TRXC) +32%, Heat Biologics (HTBX) +16%.Losers: Vir Biotechnology (VIR) -29%, NanoViricides (NNVC) -16%, ASLAN Pharmaceutica...
Ovid Therapeutics (OVID) +73% after soticlestat deal with Takeda.KemPharm (KMPH) +69% on FDA approval of ADHD drug.Ocugen, Inc. (OCGN) +39% on Indian partner’s COVID-19 vaccine efficacy data.Asensus Surgical (TRXC) +33% on FDA clearance for Senhance Surgical System....
Takeda Pharmaceutical (TAK) inks agreement with Ovid Therapeutics (OVID) to secure global rights from Ovid to develop and commercialize soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome ((DS)) and Lennox-Gastaut syndr...
− Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales − Potential first-in-class therapy reduced seizure frequency in children w...
3 Penny Stocks To Buy According To These Top Analysts This weekend we discussed the idea of penny stocks and analyst ratings. The biggest take-away is that forecasts should be just one small part of your research process. Only going by an analyst recommendation could actually pose c...
I recommended OVID for OV935 but disliked OV101. In December, OVID fell drastically after OV101's failure. OV935 thesis still stands, however, the numbers are now different. This article was written after some asked for my current opinion on the stock. For further details se...
We revisit 'Tier 4' biotech concern Ovid Therapeutics for the first time since last summer. The shares cratered in December after failed trial results from its primary drug candidate. However, the company is still well funded and has some other 'shots on goal' in its pipeline. ...
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index ...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. All three major stock market indexes closed at all-time highs Friday as D.C. lawmakers appeared to make progress toward passing a COVID stimu...
Gainers: NanoVibronix (NAOV) +99%.Merrimack Pharmaceuticals (MACK) +46%.Catabasis Pharmaceuticals (CATB) +44%.Tredegar (TG) +27%.Intec Pharma (NTEC) +27%.Kingsway Financial Services (KFS) +25%.Sequential Brands (SQBG) +23%.Sequans Communications (SQNS) +20%.Mmtec (MTC) +20%.Callon Petrol...
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...